期刊文献+

RGC-32和E—cadherin在胰腺癌中的表达及其临床病理学意义 被引量:1

Expressions of RGC-32 and E-cadherin in pancreatic cancer and their clinicopathological significance
原文传递
导出
摘要 目的探讨RGC-32和E—cadherin蛋白在胰腺癌组织中的表达,分析其临床病理学意义以及两种蛋白表达之间的相关性。方法采用免疫组织化学sP法检测42例胰腺癌、12例慢性胰腺炎和8例正常胰腺组织中RGC-32和E—cadherin蛋白的表达。结果RGC.32主要表达于胰腺腺泡细胞胞质内;E—cadherin主要表达于正常胰腺和慢性胰腺炎组织胰腺腺泡细胞胞膜,而在胰腺癌中则可出现胞质表达和(或)表达减弱等异常表达。胰腺癌组织中RGC-32的阳性表达率以及E—cadherin异常表达率分别为78.6%(33/42)和54.8%(23/42),均显著高于正常胰腺组织的37.5%(3/8)和0以及慢性胰腺炎组织41.7%(5/12)和8.3%(1/12)(P值均〈0.05)。胰腺癌组织RGC一32表达与肿瘤淋巴结转移和TNM分期有关(P值分别为0.016、0.025),而与患者的年龄、性别及肿瘤分化程度无关(P值分别为0.831、1.000、0.629);E—cadherin异常表达与胰腺癌分化程度、淋巴结转移和TNM分期有关(P值分别为0.024、0.004、0.004),而与患者年龄、性别无关(P值分别为0.970、1.000)。RGC-32的阳性表达率与E—cadherin异常表达率呈正相关(r=0.458,P〈0.01)。结论胰腺癌组织中RGC-32阳性表达率及E—cadherin异常表达率均显著升高,RGC-32可能通过调控上皮问质转化过程参与胰腺癌的侵袭和转移。 Objective To investigate the expressions of RGC-32 and E-cadherin in pancreatic cancer and analyze their clinicopathological significance and the correlation with each other. Methods SP immunohistochemistry was used to detect the expressions of RGC-32 and E-cadherin in 42 cases of pancreatic cancer tissues, 12 cases of chronic pancreatitis tissues and 8 cases of normal pancreatic tissues. Results The positive staining for RGC-32 was predominantly observed in the cytoplasm of pancreatic acinar cells. The positive staining for E-cadherin was mainly observed in the cytomembrane of normal pancreatic and chronic pancreatitis acinar cells, but aberrant expression (cytoplasm expression and (or) weaker expression) could be found in pancreatic cancer cells. The positive expression rate of RGC-32 and aberrant expression rate of E- cadherin were 78.6% (33/42) and 54.8% (23/42) , respectively, in pancreatic cancer tissues, which were significantly higher than those in normal pancreatic tissues [ 37.5% (3/8) and 0 ] and chronic pancreatitis [41.7% (5/12) and 8.3% (1/12) with statisticai significance, P 〈0.05 ]. The expression of RGC-32 in pancreatic cancer was associated with lymph node metastasis and TNM staging (P =0.016, 0.025, respectively),but not with age, gender and differentiation degree ( P =0. 831 , 1. 000, 0. 629, respectively). The aberrant expression of E-cadherin was associated with differentiation degree, lymph node metastasis and TNM staging (P = 0. 024,0. 004, 0. 004, respectively) , but not with age and gender (P = 0. 970,1. 000, respectively). A significantly positive correlation was found between positive expression rate of RGC-32 and aberrant expression rate of E-cadherin (r =0. 458, P 〈0.01 ). Conclusions Both positive expression rate of RGC-32 and aberrant expression rate of E-cadherin are up-regulated significantly in pancreatic cancer tissues and RGC-32 may he involved in the invasion and metastasis of pancreatic cancer by regulating epithelial mesen
出处 《中华胰腺病杂志》 CAS 2012年第3期173-176,共4页 Chinese Journal of Pancreatology
基金 教育部高等学校博士学科点专项科研基金(20110142110013)
关键词 胰腺肿瘤 免疫组织化学 RGC-32 上皮-钙黏素 上皮间质转化 Pancreatic neoplasmas lmmunohistochemistry Response gene to complement-32 Epithelial-cadherin Epithelial-mesenchymal transition
  • 相关文献

参考文献16

  • 1Badea TC,Niculescu FI,Soane L. Molecular cloning and characterization of RGC-32,a novel gene induced by complement activation in oligodendrocytes[J].Journal of Biological Chemistry,1998.26977-26981. 被引量:1
  • 2Badea T,Niculescu F,Soane L. RC C-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase[J].Journal of Biological Chemistry,2002.502-508. 被引量:1
  • 3Li F,Luo Z,Huang W. Response gene to complement 32,a novel regulator for transforming growth factor-beta-induced smooth muscle differentiation of neural crest cells[J].Journal of Biological Chemistry,2007.10133-10137. 被引量:1
  • 4Fosbrink M,Cudrici C,Niculescu F. Overexpression of RGC-32 in colon cancer and other tumors[J].Experimental and Molecular Pathology,2005.116-122. 被引量:1
  • 5SaigusaK,Imoto I,Tanikawa C. RGC32,a novel p53-inducible gene,is located on centrosomes during mitosis and results in G2/M arrest[J].Oncogene,2007.1110-1121. 被引量:1
  • 6Kang Y,Siegel PM,Shu W. A multigenic program mediating breast cancer metastasis to bone[J].Cancer Cell,2003.537-549. 被引量:1
  • 7Chandran UR,Ma C,Dhir R. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process[J].BMC Cancer,2007.64.doi:10.1186/1471-2407-7-64. 被引量:1
  • 8Jawhari A,Jordan S,Poole S. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma:relationship with patient survival[J].Gastroenterology,1997.46-54. 被引量:1
  • 9Ellenrieder V,Hendler SF,Boeck W. Transforming growth factor betal treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation[J].Cancer Research,2001.4222-4228. 被引量:1
  • 10Zhao S,Venkatasubbarao K,Lazor JW. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells[J].Cancer Research,2008.4221-4228. 被引量:1

同被引文献30

  • 1Hidalgo M, Pancreatic cancer. N Engl J Med 2010; 362:1605-1617 [PMID: 20427809 DOI: 10.1056/ NEJMra0901557]. 被引量:1
  • 2Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Btichler MW, Neoptolemos JP. hffluence of resection margins and treatment on survival in patients with pancreatic cancer: rneta- analysis of randomized controlled trials. Arch Surg 2008; 143: 75-183; discussion 183 [PMID: 18209156 DOI: 10.1001/archsurg.2007.171. 被引量:1
  • 3Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. Pancreatic cancer stern ceils: emerging target for designing novel therapy. Cancer Lett 2013; 338:94-100 [PMID: 22445908 DOI: 10.1016/ j.canlet.2012.03.018]. 被引量:1
  • 4Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells, lnt J Biochem Cell Biol 2012; 44:2144-2151 [PMID: 22981632 DOI: 10.1016/j.biocel.2012.08.022]. 被引量:1
  • 5Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ, Tang DG. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009; 27:993-1005 [PMID: 19415763 DOI: 10.1002/stem.29]. 被引量:1
  • 6Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high- throughput screening. Cell 2009; 138:645-659 [PMID: 19682730 DOI: 10.1016/j.cell.2009.06.034]. 被引量:1
  • 7Antoszczak M, Huczyfiski A. Anticancer activity of polyether ionophore-salinomycin. Anticancer Agents Med Chem 2015; 15:575-591 [PMID: 25553435]. 被引量:1
  • 8Arafat K, Iratni R, Takahashi T, Parekh K, A1 Dhaheri Y, Adrian TE, Attoub S. Inhibitory effects of salinomycin on cell survival, colony growth, migration, and invasion of human non-small cell lung cancer A549 and LNM35: Involvement of NAG-1. PLoS One 2013; 8:e66931 [PMID: 23805285 DOI: 10.1371/journal.pone.0066931]. 被引量:1
  • 9Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, Wu SM, Cheng P, Zhang Y, Shen M, Wang CF, Lu J, Zhou YQ, Xu XF, Xu L, Guo CY. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One 2012; 7:e50638 [PMID: 23284640 DOI: 10.1371/journal.pone.0050638]. 被引量:1
  • 10Calzolari A, Saulle E, De Angelis ML, Pasquini L, Boe A, Pelacchi F, Ricci-Vitiani L, Baiocchi M, Testa U. Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma ceU lines. PLoS One 2014; 9:e94438 [PM1D: 24740347 DOI: 10.1371/journal. pone.0094438]. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部